1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVENESS ANALYSIS 18
2 MARKET INTRODUCTION
2.1 DEFINITION 19
2.2 SCOPE OF THE STUDY 19
2.3 RESEARCH OBJECTIVE 19
2.4 MARKET STRUCTURE 19
2.5 ASSUMPTIONS & LIMITATIONS 20
3 RESEARCH METHODOLOGY
3.1 DATA MINING 21
3.2 SECONDARY RESEARCH 22
3.3 PRIMARY RESEARCH 23
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24
3.5 FORECASTING TECHNIQUES 25
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
3.6.1 BOTTOM-UP APPROACH 27
3.6.2 TOP-DOWN APPROACH 27
3.7 DATA TRIANGULATION 28
3.8 VALIDATION 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30
4.2.2 LAUNCH OF COMBINATION DRUGS 30
4.3 RESTRAINTS 31
4.3.1 COMPLEX REGULATORY REQUIREMENTS 31
4.4 OPPORTUNITIES 32
4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 33
5.1.1 R&D AND DESIGNING 34
5.1.2 MANUFACTURING 34
5.1.3 DISTRIBUTION & SALES 34
5.1.4 POST-SALES SERVICES 34
5.2 PORTER’S FIVE FORCES MODEL 35
5.2.1 BARGAINING POWER OF SUPPLIERS 36
5.2.2 BARGAINING POWER OF BUYERS 36
5.2.3 THREAT OF NEW ENTRANTS 36
5.2.4 THREAT OF SUBSTITUTES 36
5.2.5 RIVALRY 36
5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37
5.3.1 OVERVIEW 37
5.3.2 IMPACT ON SUPPLY CHAIN 37
5.3.3 IMPACT ON PRODUCTION 38
6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS
6.1 OVERVIEW 40
6.2 QUINOLONES 42
6.3 Î’-LACTAM & CEPHALOSPORINS 43
6.4 AMINOGLYCOSIDES 44
6.5 PENICILLIN 44
6.6 AZOLES 45
7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION
7.1 OVERVIEW 46
7.2 URETHRITIS 47
7.3 CYSTITIS 48
7.4 PYELONEPHRITIS 48
8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN
8.1 OVERVIEW 49
8.2 ESCHERICHIA COLI 50
8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51
8.4 KLEBSIELLA PNEUMONIAE 51
8.5 PROTEUS MIRABILIS 52
8.6 ENTEROCOCCUS FAECALIS 52
9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER
9.1 OVERVIEW 53
9.2 HOSPITALS 54
9.3 CLINICS 54
9.4 SELF-ADMINISTERED 55
10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION
10.1 OVERVIEW 56
10.2 AMERICAS 58
10.2.1 NORTH AMERICA 61
10.2.1.1 US 64
10.2.1.2 CANADA 67
10.2.2 LATIN AMERICA 70
10.3 EUROPE 73
10.3.1 WESTERN EUROPE 76
10.3.1.1 GERMANY 80
10.3.1.2 FRANCE 83
10.3.1.3 UK 86
10.3.1.4 ITALY 89
10.3.1.5 SPAIN 92
10.3.1.6 REST OF WESTERN EUROPE 95
10.3.2 EASTERN EUROPE 98
10.4 ASIA-PACIFIC 101
10.4.1 CHINA 105
10.4.2 INDIA 108
10.4.3 JAPAN 111
10.4.4 AUSTRALIA 114
10.4.5 SOUTH KOREA 117
10.4.6 REST OF ASIA-PACIFIC 120
10.5 MIDDLE EAST & AFRICA 123
10.5.1 MIDDLE EAST 126
10.5.2 AFRICA 129
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 132
11.2 COMPETITIVE BENCHMARKING 133
11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2020 134
11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134
11.4.1 PRODUCT APPROVALS AND LAUNCHES 134
11.4.2 ACQUISITIONS 134
11.5 FINANCIAL MATRIX 135
12 COMPANY PROFILES
12.1 PFIZER INC. 136
12.1.1 COMPANY OVERVIEW 136
12.1.2 FINANCIAL OVERVIEW 137
12.1.3 PRODUCTS/SERVICES OFFERED 138
12.1.4 KEY DEVELOPMENTS 138
12.1.5 SWOT ANALYSIS 138
12.1.6 KEY STRATEGIES 139
12.2 NOVO NORDISK A/S 140
12.2.1 COMPANY OVERVIEW 140
12.2.2 FINANCIAL OVERVIEW 140
12.2.3 PRODUCTS/SERVICES OFFERED 141
12.2.4 KEY DEVELOPMENTS 141
12.2.5 SWOT ANALYSIS 141
12.2.6 KEY STRATEGIES 141
12.3 NOVARTIS AG 142
12.3.1 COMPANY OVERVIEW 142
12.3.2 FINANCIAL OVERVIEW 142
12.3.3 PRODUCTS/SERVICES OFFERED 143
12.3.4 KEY DEVELOPMENTS 143
12.3.5 SWOT ANALYSIS 143
12.3.6 KEY STRATEGIES 144
12.4 MERCK & CO., INC. 145
12.4.1 COMPANY OVERVIEW 145
12.4.2 FINANCIAL OVERVIEW 145
12.4.3 PRODUCTS/SERVICES OFFERED 146
12.4.4 KEY DEVELOPMENTS 146
12.4.5 SWOT ANALYSIS 146
12.4.6 KEY STRATEGIES 146
12.5 ELI LILY AND COMPANY 147
12.5.1 COMPANY OVERVIEW 147
12.5.2 FINANCIAL OVERVIEW 147
12.5.3 PRODUCTS/SERVICES OFFERED 148
12.5.4 KEY DEVELOPMENTS 148
12.5.5 SWOT ANALYSIS 148
12.5.6 KEY STRATEGIES 148
12.6 ALLERGAN 149
12.6.1 COMPANY OVERVIEW 149
12.6.2 FINANCIAL OVERVIEW 149
12.6.3 PRODUCTS/SERVICES OFFERED 150
12.6.4 KEY DEVELOPMENTS 150
12.6.5 SWOT ANALYSIS 150
12.6.6 KEY STRATEGIES 150
12.7 CIPLA INC. 151
12.7.1 COMPANY OVERVIEW 151
12.7.2 FINANCIAL OVERVIEW 151
12.7.3 PRODUCTS/SERVICES OFFERED 151
12.7.4 KEY DEVELOPMENTS 151
12.7.5 SWOT ANALYSIS 152
12.7.6 KEY STRATEGIES 152
12.8 TEVA PHARMACEUTICALS 153
12.8.1 COMPANY OVERVIEW 153
12.8.2 FINANCIAL OVERVIEW 153
12.8.3 PRODUCTS/SERVICES OFFERED 154
12.8.4 KEY DEVELOPMENTS 154
12.8.5 SWOT ANALYSIS 154
12.8.6 KEY STRATEGIES 155
12.9 GLAXOSMITHKLINE PLC 156
12.9.1 COMPANY OVERVIEW 156
12.9.2 FINANCIAL OVERVIEW 156
12.9.3 PRODUCTS/SERVICES OFFERED 157
12.9.4 KEY DEVELOPMENTS 157
12.9.5 SWOT ANALYSIS 157
12.9.6 KEY STRATEGIES 157
12.10 BAYER AG 158
12.10.1 COMPANY OVERVIEW 158
12.10.2 COMPANY VALUE 158
12.10.3 FINANCIAL OVERVIEW 159
12.10.4 PRODUCTS/SERVICES OFFERED 159
12.10.5 KEY DEVELOPMENTS 159
12.10.6 SWOT ANALYSIS 160
12.10.7 KEY STRATEGIES 160
13 APPENDIX
13.1 REFERENCES 161
13.2 RELATED REPORTS 161
14 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23
TABLE 3 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 41
TABLE 4 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2020-2027 (USD MILLION) 42
TABLE 5 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 42
TABLE 6 GLOBAL URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY REGION, 2020-2027 (USD MILLION) 43
TABLE 7 GLOBAL URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 43
TABLE 8 GLOBAL URINARY TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2020-2027 (USD MILLION) 44
TABLE 9 GLOBAL URINARY TRACT INFECTION MARKET, FOR PENICILLIN, BY REGION, 2020-2027 (USD MILLION) 44
TABLE 10 GLOBAL URINARY TRACT INFECTION MARKET, FOR AZOLES, BY REGION, 2020-2027 (USD MILLION) 45
TABLE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 47
TABLE 12 GLOBAL URINARY TRACT INFECTION MARKET, FOR URETHRITIS, BY REGION, 2020-2027 (USD MILLION) 47
TABLE 13 GLOBAL URINARY TRACT INFECTION MARKET, FOR CYSTITIS, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 14 GLOBAL URINARY TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 15 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 50
TABLE 16 GLOBAL URINARY TRACT INFECTION MARKET, FOR ESCHERICHIA COLI, BY REGION, 2020-2027 (USD MILLION) 50
TABLE 17 GLOBAL URINARY TRACT INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2020-2027 (USD MILLION) 51
TABLE 18 GLOBAL URINARY TRACT INFECTION MARKET, FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2020-2027 (USD MILLION) 51
TABLE 19 GLOBAL URINARY TRACT INFECTION MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2020-2027 (USD MILLION) 52
TABLE 20 GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION, 2020-2027 (USD MILLION) 52
TABLE 21 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 54
TABLE 22 GLOBAL URINARY TRACT INFECTION MARKET, FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 54
TABLE 23 GLOBAL URINARY TRACT INFECTION MARKET, FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 54
TABLE 24 GLOBAL URINARY TRACT INFECTION MARKET, FOR SELF-ADMINISTERED, BY REGION, 2020-2027 (USD MILLION) 55
TABLE 25 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 57
TABLE 26 AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 58
TABLE 27 AMERICAS: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 58
TABLE 28 AMERICAS: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 59
TABLE 29 AMERICAS: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 59
TABLE 30 AMERICAS: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
TABLE 31 AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 60
TABLE 32 AMERICAS: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 60
TABLE 33 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 61
TABLE 34 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 61
TABLE 35 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 62
TABLE 36 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 62
TABLE 37 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 63
TABLE 38 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 63
TABLE 39 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 63
TABLE 40 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 64
TABLE 41 US: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 64
TABLE 42 US: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 65
TABLE 43 US: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 65
TABLE 44 US: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 66
TABLE 45 US: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 66
TABLE 46 CANADA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 67
TABLE 47 CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 67
TABLE 48 CANADA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 49 CANADA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68
TABLE 50 CANADA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 69
TABLE 51 CANADA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 69
TABLE 52 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 70
TABLE 53 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 70
TABLE 54 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 71
TABLE 55 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72
TABLE 56 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 72
TABLE 57 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 72
TABLE 58 EUROPE: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 73
TABLE 59 EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 73
TABLE 60 EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 74
TABLE 61 EUROPE: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 74
TABLE 62 EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 75
TABLE 63 EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 75
TABLE 64 EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 75
TABLE 65 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 76
TABLE 66 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 77
TABLE 67 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 77
TABLE 68 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 78
TABLE 69 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
TABLE 70 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 79
TABLE 71 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 79
TABLE 72 GERMANY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 80
TABLE 73 GERMANY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 80
TABLE 74 GERMANY: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 81
TABLE 75 GERMANY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81
TABLE 76 GERMANY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 82
TABLE 77 GERMANY: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 82
TABLE 78 FRANCE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 83
TABLE 79 FRANCE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 83
TABLE 80 FRANCE: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 84
TABLE 81 FRANCE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84
TABLE 82 FRANCE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 85
TABLE 83 FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 85
TABLE 84 UK: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 86
TABLE 85 UK: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 86
TABLE 86 UK: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 87
TABLE 87 UK: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 87
TABLE 88 UK: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 88
TABLE 89 UK: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 88
TABLE 90 ITALY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 89
TABLE 91 ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 89
TABLE 92 ITALY: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 90
TABLE 93 ITALY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90
TABLE 94 ITALY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 91
TABLE 95 ITALY: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 91
TABLE 96 SPAIN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 92
TABLE 97 SPAIN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 92
TABLE 98 SPAIN: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 93
TABLE 99 SPAIN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 93
TABLE 100 SPAIN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 94
TABLE 101 SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 94
TABLE 102 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 95
TABLE 103 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 95
TABLE 104 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 96
TABLE 105 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 96
TABLE 106 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 97
TABLE 107 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 97
TABLE 108 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 98
TABLE 109 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 98
TABLE 110 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 99
TABLE 111 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 99
TABLE 112 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 100
TABLE 113 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 100
TABLE 114 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 101
TABLE 115 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 102
TABLE 116 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 102
TABLE 117 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 103
TABLE 118 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 103
TABLE 119 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 104
TABLE 120 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 104
TABLE 121 CHINA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 105
TABLE 122 CHINA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 105
TABLE 123 CHINA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 106
TABLE 124 CHINA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 106
TABLE 125 CHINA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 107
TABLE 126 CHINA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 107
TABLE 127 INDIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 108
TABLE 128 INDIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 108
TABLE 129 INDIA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 109
TABLE 130 INDIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 109
TABLE 131 INDIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 110
TABLE 132 INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 110
TABLE 133 JAPAN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 111
TABLE 134 JAPAN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 111
TABLE 135 JAPAN: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 112
TABLE 136 JAPAN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 112
TABLE 137 JAPAN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 113
TABLE 138 JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 113
TABLE 139 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 114
TABLE 140 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 114
TABLE 141 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 115
TABLE 142 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 115
TABLE 143 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 116
TABLE 144 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 116
TABLE 145 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 117
TABLE 146 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 117
TABLE 147 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 118
TABLE 148 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 118
TABLE 149 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 119
TABLE 150 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 119
TABLE 151 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 120
TABLE 152 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 120
TABLE 153 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 121
TABLE 154 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121
TABLE 155 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 122
TABLE 156 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 122
TABLE 157 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 123
TABLE 158 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 123
TABLE 159 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 124
TABLE 160 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 124
TABLE 161 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 125
TABLE 162 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 125
TABLE 163 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 125
TABLE 164 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 126
TABLE 165 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 126
TABLE 166 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 127
TABLE 167 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 127
TABLE 168 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 128
TABLE 169 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 128
TABLE 170 AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 129
TABLE 171 AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 129
TABLE 172 AFRICA: URINARY TRACT INFECTION MARKET, FOR Î’-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 130
TABLE 173 AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130
TABLE 174 AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 131
TABLE 175 AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 131
TABLE 176 MAJOR MANUFACTURERS RANKING, 2020 134
TABLE 177 PRODUCT APPROVALS AND LAUNCHES 134
TABLE 178 ACQUISITIONS 134
TABLE 179 PFIZER INC.: PRODUCTS/SERVICES OFFERED 138
TABLE 180 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED 141
TABLE 181 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 143
TABLE 182 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 146
TABLE 183 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148
TABLE 184 ALLERGAN: PRODUCTS/SERVICES OFFERED 150
TABLE 185 CIPLA INC.: PRODUCTS/SERVICES OFFERED 151
TABLE 186 CIPLA INC.: KEY DEVELOPMENTS 151
TABLE 187 TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154
TABLE 188 TEVA PHARMACEUTICALS: KEY DEVELOPMENTS 154
TABLE 189 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 157
TABLE 190 BAYER AG: COMPANY VALUE 158
TABLE 191 BAYER AG.: PRODUCTS/SERVICES OFFERED 159
15 LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 17
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS, BY REGION, 2020 18
FIGURE 3 GLOBAL URINARY TRACT INFECTION MARKET: STRUCTURE 19
FIGURE 4 BOTTOM-UP AND TOP-DOWN APPROACHES 26
FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL URINARY TRACT INFECTION (UTI) MARKET 29
FIGURE 6 DRIVER IMPACT ANALYSIS 31
FIGURE 7 RESTRAINT IMPACT ANALYSIS 32
FIGURE 8 VALUE CHAIN: GLOBAL URINARY TRACT INFECTION MARKET 33
FIGURE 9 PORTER’S FIVE FORCES ANALYSIS: GLOBAL URINARY TRACT INFECTION MARKET 35
FIGURE 10 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020 AND 2027 (USD MILLION) 41
FIGURE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 46
FIGURE 12 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020 AND 2027 (USD MILLION) 49
FIGURE 13 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 53
FIGURE 14 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 57
FIGURE 15 AMERICAS: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 58
FIGURE 16 NORTH AMERICA: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 61
FIGURE 17 EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 73
FIGURE 18 WESTERN EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 76
FIGURE 19 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 101
FIGURE 20 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 123
FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS 133
FIGURE 22 SALES & OPERATING INCOME MARGIN, 2020 135
FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE, 2020 135
FIGURE 24 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 137
FIGURE 25 PFIZER INC.: SWOT ANALYSIS 138
FIGURE 26 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 140
FIGURE 27 NOVO NORDISK A/S: SWOT ANALYSIS 141
FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 142
FIGURE 29 NOVARTIS AG: SWOT ANALYSIS 143
FIGURE 30 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 145
FIGURE 31 MERCK & CO., INC.: SWOT ANALYSIS 146
FIGURE 32 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 147
FIGURE 33 ELI LILY AND COMPANY: SWOT ANALYSIS 148
FIGURE 34 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT 149
FIGURE 35 ALLERGAN: SWOT ANALYSIS 150
FIGURE 36 CIPLA INC.: SWOT ANALYSIS 152
FIGURE 37 TEVA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 38 TEVA PHARMACEUTICALS: SWOT ANALYSIS 154
FIGURE 39 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 156
FIGURE 40 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 157
FIGURE 41 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT 159
FIGURE 42 BAYER AG.: SWOT ANALYSIS 160
